SINCE 2009
OPERATING RECORD
Corporate identity and public records are available in the Legal Hub.
PURE-PLAY B2B CDMO · PUBLIC DUE DILIGENCE · PROJECT SCOPE
GLOBAL CDMO PORTFOLIO & CORPORATE EVIDENCE.
Olympia Biosciences™ is a pure-play B2B Contract Development and Manufacturing Organization based in Gdynia, Poland. Current public corporate and certificate records are available in the Legal Hub; product, evidence and deliverables are defined within the agreed project scope. Olympia Biosciences™ has no brands of its own.
THE PUBLIC EVIDENCE MATRIX.
Public diligence starts with current Legal Hub records and a project-specific evidence review.
PURE-PLAY B2B
NO BRANDS OF OUR OWN
Olympia Biosciences™ does not operate consumer supplement brands.
LEGAL HUB
CURRENT PUBLIC RECORDS
Certificate status and scope are published in the Legal Hub.
PROJECT EVIDENCE
ANALYTICAL STRATEGY
Qualified independent laboratories perform evidentiary testing where required.
OPERATING COVENANT
SCIENTIFIC TRUTH BEFORE REVENUE.
Project suitability is assessed against the available evidence, manufacturing constraints and the agreed scope before a production decision is made.
Scientific Validity
If a composition cannot survive peer-reviewed clinical scrutiny or physical-chemistry validation, we will not manufacture it, regardless of the budget.
Human Continuity
The written brief is reviewed and routed to an appropriate IOC contact based on project phase and requirements.
Aligned Outcomes
We do not hide behind the market operator's legal responsibility. We make sure our partner understands the risk, the evidence, and the decision before the product leaves our hands.
Human-Led, AI-Enabled
A project brief defines the formulation, evidence, regulatory path, scope and ownership terms before manufacturing is considered.
PUBLIC MANUFACTURING RECORD
ONE PUBLICLY DISCLOSED CASE.
IOC served as contract manufacturer for Carocelle, a micellar technology developed by Lycotec Ltd, a Cambridge (UK) biotech company founded by a former University of Cambridge researcher (2016 and 2017 management reports of Adiuvo Investments S.A., Warsaw Stock Exchange; Companies House 07397545).
IOC served as contract manufacturer for Carocelle, a micellar technology developed by Lycotec Ltd, a Cambridge (UK) biotech company founded by a former University of Cambridge researcher (2016 and 2017 management reports of Adiuvo Investments S.A., Warsaw Stock Exchange; Companies House 07397545).
Two consecutive public reporting periods provide a directly verifiable manufacturing reference—without disclosing confidential client work.
PROJECT GOVERNANCE
SCIENTIFIC LEADERSHIP.
Founder Synthesis × Execution System
A project-specific route connects formulation evidence, manufacturing constraints, analytical strategy and agreed deliverables. The scope is reviewed before a production decision is made.
Enterprise-level formulation requires project-specific oversight. The written brief is reviewed against the project's phase and regulatory requirements and routed to an appropriate IOC contact.
Olimpia Baranowska
CEO & Scientific Director
M.Sc. Eng. in Technical Physics and Applied Mathematics; Ph.D. Candidate in Medical Sciences (Phlebology). Co-Founder, CEO and Scientific Director of Olympia Biosciences™. Featured in Forbes Polska: »Algorytm w kapsułce«.
Haris Haroon
Manager of B2B Sales & Strategic Project Management
Educated as a Medical Doctor and Surgeon (MBBS) with postgraduate training in Sports Management. He brings a clinical perspective into regulated-product manufacturing, regulatory alignment, and supply-chain execution.
Izabela Łagód
Manager of B2B Sales & Strategic Project Management
M.Sc. in Medical Biology with a specialization in Molecular and Biochemical Diagnostics. Her laboratory background spans advanced clinical research, molecular biology, and biochemical analysis, connecting molecular science with disciplined industrial execution.
PROPRIETARY TECHNOLOGY
INDUSTRIALIZED DELIVERY SYSTEMS.
Where technically suitable, Olympia evaluates delivery-system options within the project's formulation, manufacturing and evidence requirements. Suitability is determined through the agreed development scope.
Registered Innovation Assets
Registered innovation marks and their current ownership records are available through the Legal Hub.
Collagen Development Scope
Material selection, format and evidence needs are evaluated within the agreed development scope; suitability is not assumed before review.
Clean-Label Excipient Substitution
Where technically suitable, we evaluate plant-derived, clean-label alternatives to conventional anti-caking, flow, lubrication, and binding excipients. Every substitution undergoes rigorous formulation, stability, and market-specific validation.
Evidence and Analytical Strategy
Evidence review and analytical strategy are defined within the project scope. Qualified independent laboratories perform evidentiary testing where required.
THE FINAL GATE
INITIATE R&D DUE DILIGENCE.
Supplement Paid Discovery Core starts at EUR 4,500 for a defined, confidential Stage I scope. Market-Ready pre-PO adds EUR 4,000 for specifications, COA/source-lock requirements, a testing plan, a stability protocol, shelf-life rationale, per-jurisdiction labels, warnings and claims, and a registration route with required documents and certificates; a one-SKU, one-jurisdiction Core plus Market-Ready package totals EUR 8,500. Actual Stage II batch records, COAs, results and release remain excluded. FSMP and medical-nutrition programmes are individually scoped and quoted without a public price.
Submit a written scoped request. The team will review the brief and reply in writing.
EXPLORE MANUFACTURING INTELLIGENCE
Formulation TechnologyFormulation options are assessed against the product brief and agreed scope.EXPLORE ›Production Formats & MOQ ReferenceHard capsules 150K, softgels 300K, sachets 75K — confirmed dosage formats and packaging options.EXPLORE ›Scale-Up to Commercial ProductionStaged route from prototype to production within the agreed project scope.EXPLORE ›ISO 27001 Formula IP ProtectionInformation-security governance that protects client formulas throughout the manufacturing relationship.EXPLORE ›Paid Discovery: Controlled R&D Due DiligenceThe mandatory entry gate — scoped technical evaluation before any manufacturing engagement.EXPLORE ›Science-First ManifestoThe operating doctrine: evidence, manufacturability and responsible technical decision-making.EXPLORE ›
Strictly B2B / Educational R&D Disclaimer
The pharmacokinetic data, clinical references, and scientific literature referenced on this page are provided strictly for B2B formulation, educational, and R&D purposes for medical professionals, pharmacologists, and brand developers. Olympia Biosciences™ operates solely as a Contract Development and Manufacturing Organization (CDMO) and does not manufacture, market, or sell consumer end-products.
Global Regulatory & No Health Claims. Nothing on this page constitutes a health claim, medical claim, or disease-risk-reduction claim within the meaning of EU Regulation (EC) No 1924/2006, the U.S. Dietary Supplement Health and Education Act (DSHEA), or other global regulatory frameworks. These statements and raw data have not been evaluated by the Food and Drug Administration (FDA), European Food Safety Authority (EFSA), or Therapeutic Goods Administration (TGA). The raw active pharmaceutical ingredients (APIs) and formulations discussed are not intended to diagnose, treat, cure, or prevent any disease.
Client Responsibility. The B2B client who commissions a formulation from Olympia Biosciences™ is responsible for market-specific regulatory compliance, health claim authorisation, labelling and marketing of its finished product, as defined by the applicable agreement.